Amgen (AMGN)

Amgen reported Q3 earnings of $1.49 on net income of $1.5 billion versus $1.23 on net income of $1.3 billion in the year ago period. Total revenue decreased 2% during the quarter to $3.8 billion.
"Our third quarter results reflect the continued stability of our core businesses in the face of increased competition," said Kevin Sharer, chairman & chief executive officer. "We are pleased by the results of clinical studies for denosumab and Vectibix that we recently presented at a scientific meeting, and look forward to making these innovative medicines available to patients in their respective indications."

Oct 22 · 10:47:00 AM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto